Camilo Colaco

ImmunoBiology

Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.

dont miss

The immunobiology of immunotherapy

Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.

EVEN MORE SEMINARS

  • Dr Anita Rose: Speaking at the Oncology Convention

    Dr Anita Rose
    The Raphael Hospital

    Cognitive Issues in Multiple Sclerosis

  • Dr Ioanna Nixon: Speaking at the Oncology Convention

    Dr Ioanna Nixon
    Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde

    When the oncologist meets the patient: value of compassion. How well are we doing?

  • Mylaine Riobe MD, FABOIM, FACOG: Speaking at the Oncology Convention

    Mylaine Riobe MD, FABOIM, FACOG
    Riobe Institute of Integrative Medicine

    Cancer is not random! Evolving mechanisms for cancer causation and prevention

  • Merina Ahmed: Speaking at the Oncology Convention

    Merina Ahmed
    Royal Marsden NHS foundation Trust

    Stereotactic Radiotherapy for lung tumours and oligometastatic disease

  • Gareth Thomas BDS, MScD, PhD, FDSRCS, FRCPath: Speaking at the Oncology Convention

    Gareth Thomas BDS, MScD, PhD, FDSRCS, FRCPath
    University Hospital Southampton NHS Foundation Trust.

    Targeted therapies: aiming at the tumour micro-environment